Novogen Limited Touts Successful Proof-Of-Concept Studies For Trx-1

Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells * Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15 * Yale researchers present the latest in vitro and in vivo results at Drug Discovery and Therapy 2014 World Congress , today announced the ... (more)

http://ift.tt/UIkjEj